Immunogenicity and Safety of Pandemic Influenza Vaccines in Adults Aged 18 - 49 Years Old

Influenza Clinical Trial

Official title:

Immunogenicity and Safety Study of GSK Biologicals' Cell Culture Derived Pandemic Influenza Vaccines GSK2590066A and GSK2592984A Administered to Healthy Adults 18 - 49 Years Old

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01236040
• Other study ID #: 114371
• Status: Completed
• Phase: Phase 1
• First received: October 28, 2010
• Last updated: May 9, 2017
• Start date: November 29, 2010
• Est. completion date: August 20, 2012

Study information

• Verified date: May 2017
• Source: GlaxoSmithKline
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will assess safety and immunogenicity of GSK Biologicals' H5N1 flu candidate vaccines GSK2590066A and GSK2340273A in healthy adults 18 - 49 years old.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 521
• Est. completion date: August 20, 2012
• Est. primary completion date: September 6, 2011
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 49 Years

Eligibility

Inclusion Criteria:

• Subjects who the investigator believes can and will comply with the requirements of the protocol.

• Written informed consent obtained from the subject.

• Male and female adults, 18-49 years of age at the time of the first vaccination.

• Satisfactory baseline medical assessment by history and physical examination.

• Safety laboratory test results within the parameters specified in the protocol.

• Access to a consistent means of telephone contact

• Female subjects of non-childbearing potential may be enrolled in the study. Female subjects of childbearing potential may be enrolled in the study, if the subject: has practiced adequate contraception for 30 days prior to vaccination, and has a negative urine pregnancy test on the day of first vaccination, and has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series.

Exclusion Criteria:

• Medical history of physician-confirmed infection with an H5N1 virus.

• Increased risk of occupational exposure to H5N1 influenza viruses.

• Previous vaccination at any time with an H5N1 vaccine, or with an oil-in water adjuvanted influenza vaccine.

• Planned administration of an adjuvanted influenza vaccine or an H5N1 pandemic vaccine during the entire study period.

• Use of any investigational or non-registered product other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.

• Presence of significant acute or chronic, uncontrolled medical or psychiatric illness.

• Presence of neurological or psychiatric diagnoses which, although stable, are deemed by the investigator to render the potential subject unable/unlikely to provide accurate safety reports.

• Evidence of current substance abuse, including alcohol, by medical history.

• Presence of a temperature >= 38.0ºC (=100.4ºF), or acute symptoms greater than "mild" severity on the scheduled date of first dose.

• Diagnosed with cancer, or treatment for cancer, within 3 years. Persons with a history of cancer who are disease-free without treatment for 3 years or more are eligible.

• Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.

• Receipt of systemic glucocorticoids within 1 month prior to study enrollment, or any other cytotoxic or immunosuppressive drug within 6 months of study enrollment.

• Receipt of any immunoglobulins and/or any blood products within 3 months of study enrollment or planned administration of any of these products during the study period.

• Any significant disorder of coagulation or treatment with warfarin derivatives or heparin. Persons receiving individual doses of low molecular weight heparin, outside of 24 hours prior to dosing, are eligible. Persons receiving prophylactic antiplatelet medications.

• An acute evolving neurological disorder or history of Guillain-Barré syndrome.

• Administration of an inactivated seasonal influenza vaccine within 14 days before the first study vaccine dose, or of any other vaccine(s) not foreseen by the study protocol within 30 days before the first study vaccine dose. The administration of live attenuated trivalent seasonal influenza virus vaccine (LAIV) is allowed.

• Planned administration of any vaccine(s) not foreseen by the study protocol through completion of the Day 42 visit. The administration of LAIV is allowed.

• Any known or suspected allergy to any constituent of influenza vaccines or to latex, or history of severe reaction to a previous influenza vaccination.

• Known pregnancy or a positive urine beta-human chorionic gonadotropin (ß-hCG) test result prior to the first study vaccine dose.

• Lactating or nursing women.

Related Conditions & MeSH terms

• Influenza
• Influenza, Human

Intervention

Biological:
• GSK Biologicals' investigational vaccine GSK2590066A
Intramuscular injection, two doses
• GSK Biologicals' investigational vaccine GSK2592984A
Intramuscular injection, two doses
• GSK Biologicals' investigational vaccine GSK2340274A
Intramuscular injection, two doses
• GSK Biologicals' investigational vaccine GSK2340273A
Intramuscular injection, two doses

Other:
• Placebo
Intramuscular injection, two doses

Locations

Country	Name	City	State
United States	GSK Investigational Site	Anaheim	California
United States	GSK Investigational Site	Austin	Texas
United States	GSK Investigational Site	Lenexa	Kansas
United States	GSK Investigational Site	Stockbridge	Georgia

Sponsors (1)

Lead Sponsor	Collaborator
GlaxoSmithKline

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Immunogenicity with respect to components of the investigational vaccine Day 0		Day 0
Primary	Immunogenicity with respect to components of the investigational vaccine Day 42		Day 42
Primary	Occurrence of Grade 3 injection site pain		During a 7-day follow-up period (Day 0 to 6) after any vaccination
Secondary	Occurrence of each solicited local symptom		During a 7-day follow-up period (Day 0 to 6) after any vaccination
Secondary	Occurrence of each solicited general symptom		During a 7-day follow-up period (Day 0 to 6) after any vaccination
Secondary	Occurrence of unsolicited adverse events (AEs)		Within 21 days (Day 0 to 20) after any vaccination
Secondary	Occurrence of AEs with medically attended visits (MAEs)		During the entire study period (from Day 0 to Month 12)
Secondary	Occurrence and relationship to vaccination of (potential) immune mediated diseases (pIMDs)		During the entire study period (from Day 0 to Month 12)
Secondary	Occurrence and relationship to vaccination of serious adverse events (SAEs)		During the entire study period (from Screening to Month 12)
Secondary	Occurrence of adverse pregnancy outcomes		During the entire study period (from Day 0 to Month 12)
Secondary	Clinical safety laboratory abnormalities		At Days 7, 28 and at Month 6.
Secondary	Immunogenicity with respect to components of the investigational vaccine in terms of hemagglutinin Inhibition (HI) antibodies		At Days 0, 21, and 42 and Months 6 and 12
Secondary	Immunogenicity with respect to components of the investigational vaccine in terms of microneutralization (MN) antibodies		Days 0, 21, and 42 and Months 6 and 12

External Links

•   Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
•   Results for study 114371 can be found on the GSK Clinical Study Register